ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Endometrial Cancer
Ovarian Cancer

Triple Negative Breast Cancer trials near Toronto, ON, CAN:

A Phase 1 Study of PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including tr ...

Enrolling
Triple Negative Breast Cancer (TNBC)
Advanced Solid Tumors Cancer
Drug: PQ203

Phase 1

ProteinQure Inc.

Toronto, Ontario, Canada

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer....

Active, not recruiting
Breast Cancer
Drug: CFI-400945
Drug: Durvalumab

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 4 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Toronto, Ontario, Canada and 197 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Toronto, Canada and 374 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 226 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 121 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Active, not recruiting
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 275 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Toronto, Canada and 506 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 192 other locations

Locations recently updated

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer...

Enrolling
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Toronto, Ontario, Canada and 148 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems